NCT00494533

Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension

Treprostinil for Untreated Symptomatic PAH Trial: A 12-Week Multicenter Randomized Double-Blind Placebo-Controlled Trial of the Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 45 (actual)
• Sponsor: United Therapeutics · Industry
• Sex: All
• Age: 16 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Multi-center, double-blind, placebo-controlled, randomized, parallel study comparing continuous intravenous (IV) Remodulin® to placebo in patients with pulmonary arterial hypertension either primary (PPH) or associated with human immunodeficiency virus (HIV) infection or collagen vascular disease).

Conditions

• Pulmonary Arterial Hypertension

Interventions

Type	Name	Description
DRUG	Remodulin (treprostinil sodium)

Timeline

• Start date: 2005-03-01
• Primary completion: 2005-10-01
• Completion: 2005-10-01
• First posted: 2007-06-29
• Last updated: 2014-01-29

Locations

14 sites across 1 country: India